Antiviral composition and method of use
Inventors
Grassauer, Andreas • Prieschl-Grassauer, Eva • Koller, Christiane • Pretsch, Alexander
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-8282969-B2
Publication Date
2012-10-09
Expiration Date
Abstract
A method for manufacturing an antiviral pharmaceutical composition for the prophylaxis or treatment of a rhinovirus infection that includes the utilization of iota-, kappa- or lambda-carrageenan or mixtures thereof.
Core Innovation
Carrageenan, including iota-, kappa-, and lambda-carrageenan, is disclosed as an active antiviral ingredient for prophylaxis and therapeutic treatment of rhinovirus infections, including acute rhinovirus infection and chronic rhinovirus infection. Iota-carrageenan is identified as giving the best antiviral results, and the disclosed approach uses a composition comprising iota-carrageenan in an antiviral effective amount as the active antiviral ingredient.
The document describes mechanisms of action across stages of the rhinovirus cycle, including virus penetration, virus replication, virus assembly, and virus release. The activity is presented as reducing rhinovirus titers and cell death, and the document relates performance to EC50 and virus titer reduction across multiple rhinovirus subtypes. The disclosed activity includes effects on primary human nasal epithelial cells.
The document further describes acceptable carrageenan mixtures and homopolymers, including mean molecular weight range fractions and low, middle, and high molecular weight fractions. Formulation and administration modalities include topical and mucosal application as preferred, with systemic administration possible. The document also describes hygiene/sanitary article coating and impregnation use using carrageenan to contact surfaces associated with rhinovirus infection.
Claims Coverage
One independent claim is explicitly provided. The claim is centered on iota-carrageenan as the active antiviral ingredient in an antiviral effective amount for treating a subject having a rhinovirus infection.
Treating a subject with a rhinovirus infection using iota-carrageenan as active antiviral ingredient
A method for treating a subject having a rhinovirus infection comprising administering to the subject a composition comprising iota-carrageenan in an antiviral effective amount as an active antiviral ingredient.
The independent claim focuses on administering an iota-carrageenan-containing composition at an antiviral effective amount to treat a subject with a rhinovirus infection, with dependent claims further specifying treatment timing, administration route and delivery forms, patient high-risk categories, optional additional pharmaceutically active compounds, and composition constraints such as iota-carrageenan concentration and iota-carrageenan weight fraction.
Stated Advantages
Reduces rhinovirus titers and cell death, including significant reductions across multiple rhinovirus subtypes and EC50-related activity.
Provides activity on primary human nasal epithelial cells.
Shows no significant development of resistance after repeated replication cycles.
Allows prophylaxis and therapeutic treatment of rhinovirus infections.
Documented Applications
Prophylaxis and therapeutic treatment of rhinovirus infections, including acute rhinovirus infection and chronic rhinovirus infection.
Topical and mucosal administration using galenic forms such as cream, gel, ointment, powder, spray, foam, lotions, gargle solution, and nose drops.
Systemic administration is stated as possible.
Coating and impregnation of hygiene/sanitary articles, including nasal tissues/papers, gloves, masks, swabs, dust masks, and lipsticks, for contact-related use.
Interested in licensing this patent?